Lisa McWilliams

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill et al. · Clinical Cancer Research · 2022 · 171 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

Novel Antibacterial Targets and Compounds Revealed by a High-Throughput Cell Wall Reporter Assay

Asha S. Nayar, Thomas J. Dougherty, Keith Ferguson et al. · Journal of Bacteriology · 2015 · 110 citations · Full text

Life Sciences, Microbiology, Antimicrobial Pharmacology +10

Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill et al. · Clinical Cancer Research · 2023 · 58 citations

Medicine, Oncology, Pharmacology +14

Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection

Lewis Mervin, Qing Cao, Ian P. Barrett et al. · ACS Chemical Biology · 2016 · 45 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17